Gloyeske Nika C, Woodard Anna H, Elishaev Esther, Yu Jing, Clark Beth Z, Dabbs David J, Bhargava Rohit
Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA.
Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):202-8. doi: 10.1097/PAI.0000000000000076.
There are a few studies that have evaluated a panel of stains on a single large data set of breast cancers, which is required for direct comparison between antibodies. The immunohistochemical panel in this study was chosen to include breast-specific markers and markers that are expressed in tumors resembling breast cancer. The individual marker positivity in decreasing order was 95% (177/186) for GATA-3, 92% (172/186) for cytokeratin (CK)7, 80% (151/189) for AR, 80% for estrogen receptor (158/198), 69% for progesterone receptor (137/198), 55% (105/190) for NY-BR-1, 52% (99/189) for mammaglobin, 31% (59/191) for vimentin, 26% (51/195) for GCDFP-15, 0.5% (1/186) for CK20, and 0% (0/188) for PAX-8. When tumors were categorized based on estrogen receptor and HER2 status; a total of 45 profiles were identified. In addition, some tumors showed an unconventional profile-although the majority of breast carcinomas were CK7-positive/CK20-negative, a CK7-negative/CK20-negative profile was seen in ∼8% of the cases. Such a profile can create confusion in investigation of a carcinoma of unknown origin. The results define the individual sensitivity of each marker and establish a baseline diagnostic profile of breast cancer in a large data set. In addition, the results support the use of immunohistochemical panel for confirming or determining breast as the source of metastasis.
有一些研究在单个大型乳腺癌数据集上评估了一组染色，这是抗体之间直接比较所必需的。本研究中的免疫组织化学 panel 被选择包括乳腺特异性标志物和在类似乳腺癌的肿瘤中表达的标志物。各个标志物的阳性率从高到低依次为：GATA-3为95%（177/186），细胞角蛋白（CK）7为92%（172/186），雄激素受体（AR）为80%（151/189），雌激素受体为80%（158/198），孕激素受体为69%（137/198），NY-BR-1为55%（105/190），乳腺珠蛋白为52%（99/189），波形蛋白为31%（59/191），GCDFP-15为26%（51/195），CK20为0.5%（1/186），PAX-8为0%（0/188）。当根据雌激素受体和HER2状态对肿瘤进行分类时，共识别出45种模式。此外，一些肿瘤表现出非传统模式——尽管大多数乳腺癌为CK7阳性/CK20阴性，但在约8%的病例中可见CK7阴性/CK20阴性模式。这种模式可能会在不明来源癌的调查中造成混淆。这些结果定义了每个标志物的个体敏感性，并在一个大型数据集中建立了乳腺癌的基线诊断模式。此外，结果支持使用免疫组织化学 panel 来确认或确定乳腺是否为转移来源。
